Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | KDM4A | O75164 | 2/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.42 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 5/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.36 |
| ▸ | KDM6B | O15054 | 2/20 | 0.36 |
| ▸ | KDM6A | O15550 | 1/20 | 0.36 |
| ▸ | TET3 | O43151 | 1/20 | 0.36 |
| ▸ | KDM4B | O94953 | 1/20 | 0.36 |
| ▸ | KDM5C | P41229 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL285234 | 0.89 | MAP2K1 (0.46) | KDM4ERAB9AL3MBTL1NPC1TP53 | |
| SCHEMBL5956817 | 0.78 | NCF1 (0.39) | KDM4ERAB9ANPC1TP53SMN1; SMN2 | |
| SCHEMBL285259 | 0.78 | CYP17A1 (0.35) | KDM4ERAB9ANPC1TP53SMN1; SMN2 | |
| SCHEMBL21816207 | 0.73 | KDM5A (0.46) | KDM4ERAB9AKDM4AEGLN1L3MBTL1 | |
| SCHEMBL1957135 | 0.71 | HTT (0.43) | KDM4EL3MBTL1ALDH1A1POLBMAPT | |
| SCHEMBL293663 | 0.70 | AURKA (0.44) | — | |
| SCHEMBL30668855 | 0.70 | KDM4E (0.54) | KDM4ERAB9ANPC1TP53SMN1; SMN2 | |
| SCHEMBL12499171 | 0.70 | KDM4E (0.58) | KDM4ERAB9AKDM4AEGLN1L3MBTL1 | |
| SCHEMBL293085 | 0.69 | LIPE (0.32) | — | |
| SCHEMBL14894644 | 0.69 | XDH (0.49) | KDM4ERAB9AKDM4AEGLN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541445-B2 | Pyrazolopyridines | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541445-B2 | Pyrazolopyridines | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541445-B2 | Pyrazolopyridines | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120178778-A1 | PYRAZOLOPYRIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178778-A1 | PYRAZOLOPYRIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178778-A1 | PYRAZOLOPYRIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-12 | — | — | US | disclosed |
| EP-2427464-A1 | PYRAZOLOPYRIDINES | Vertex Pharmaceuticals Incorporated (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129668-A1 | PYRAZOLOPYRIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178778-A1 | PYRAZOLOPYRIDINES | MAP3K5, MAP4K5, MAP3K20 | KDM4E 1638/4885RAB9A 1947/4885KDM4A 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.